Business Context and Reporting Period
This Form 8-K is a current report filed by BioSig Technologies, Inc. (not Streamex Corp.) on April 9, 2015. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensatory arrangements.
Material Changes
- Board Appointment: Jerome Zeldis, M.D., Ph.D., was appointed to the Board of Directors effective April 9, 2015.
- Compensatory Arrangement: Dr. Zeldis received a stock option grant for 300,000 shares of common stock.
- Option Terms: The exercise price is $3.99 per share (fair market value on the effective date). The options vest 100% immediately and expire seven years after the grant date.
Outlook, Risks, and Management Commentary
Management commentary indicates that Dr. Zeldis brings extensive healthcare industry experience and a background in emerging growth companies, which is expected to be a valuable resource for the Board. No specific financial guidance, risks, or contingencies are disclosed in this filing.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 300,000-share option grant.
- Confirm the terms of the BioSig Technologies, Inc. 2012 Equity Incentive Plan referenced in the grant.
- Review Dr. Zeldis's existing board commitments (Semorex, Bionor Pharma, Mali Health, PTC, Alliqua BioMedical) for potential conflicts of interest.
- Check the company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.